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A comparison of generic drug prices in
seven European countries: a
methodological analysis
Olivier J. Wouters* and Panos G. Kanavos
Abstract
Background: Policymakers and researchers frequently compare the prices of medicines between countries. Such
comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this
study was to examine methodological challenges to comparing generic drug prices.
Methods: We calculated all commonly used price indices based on 2013 IMS Health data on sales of 3156 generic
drugs in seven European countries.
Results: There were large differences in generic drug prices between countries. However, the results varied depending on
the choice of index, base country, unit of volume, method of currency conversion, and therapeutic category. The results
also differed depending on whether one looked at the prices charged by manufacturers or those charged by pharmacists.
Conclusions: Price indices are a useful statistical approach for comparing drug prices across countries, but researchers
and policymakers should interpret price indices with caution given their limitations. Price-index results are highly sensitive
to the choice of method and sample. More research is needed to determine the drivers of price differences between
countries. The data suggest that some governments should aim to reduce distribution costs for generic drugs.
Keywords: Generic medicines, Generic drugs, Prices, Expenditures, Pharmaceutical policy
Background
Many European countries are facing severe cost pres-
sures on health-care budgets, in part due to rising drug
spending. In this context, the savings from greater use of
generic drugs can help pay for other health-care services.
Yet recent European Commission reports point to mar-
ket failures for generic drugs [1, 2]. It is therefore im-
portant to regularly compare generic drug prices in
countries with similar income levels in order to give
public and private insurers a sense of whether they are
over-paying for generic drugs or not. Such comparisons
can serve as barometers of how pricing and reimburse-
ment policies are performing [3–15].
Previous comparisons of generic drug prices have
found that prices varied markedly across European and
North American countries [16–24]. However, the studies
often relied on different methods and samples, making it
difficult to compare findings. In addition, most of the ana-
lyses had small sample sizes, which may have biased the
results. Some earlier findings are also likely out of date
given how often pricing and reimbursement regulations
are changed.
As important, the impact of distribution margins and
taxes on generic drug prices has been underexplored,
even though studies indicate that those costs can account
for more than 90% of the retail price of a generic drug, i.e.,
the price charged by pharmacists to patients or third-party
payers [1]. Nearly all studies have looked at ex-
manufacturer prices, i.e., those charged by manufacturers
to wholesalers, which do not account for distribution costs.
In this study, we compared the ex-manufacturer and
retail prices of a large sample of generic drugs in seven
European countries. We calculated all commonly used
price indices to outline the methodological challenges to
comparing generic drug prices. It is critical that policy-
makers are aware of the advantages and limitations of
these types of analyses, given that the results of price
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comparisons might be used to justify changes to
pharmaceutical policies.
Methods
We acquired 2013 data from IMS Health on volumes and
sales of 200 off-patent active ingredients in seven countries
with similar income levels: Belgium, Denmark, France,
Germany, Italy, Spain, and Sweden. These ingredients were
available in 3156 strength-form combinations.1 Volumes
were recorded in doses and grams of active ingredient.2
Sales were recorded in euros based on average exchange
rates for the year.3 We excluded 213 products (6.7%, 213/
3156) with missing volume data.
We restricted our analysis to the 110 active ingredients
sold in all seven countries, which accounted for 54
(Italy) to 87% (Sweden) of total generic spend in each
country. For each ingredient, we calculated the average
price per dose and the average price per gram, both at
the ex-manufacturer and retail levels. To do this, we di-
vided total sales in euros across strength-form combina-
tions by number of doses or grams sold.4
We then calculated four indices — unweighted,
Paasche, Laspeyres, and Fisher — using prices per
gram and prices per dose [25]. Unweighted indices
(IU) were calculated as
IU ¼
X
i
pciX
i
pbi
⋅100
where p was the price of active ingredient i in the
comparator country or the base country. We selected
Germany as the base country, which takes a value of
100 in all indices.
The other indices were weighted to account for con-
sumption patterns. Paasche (IP) and Laspeyres indices
(IL) were computed as
IP ¼
X
i
pci q
c
iX
i
pbi q
c
i
⋅100
and
IL ¼
X
i
pci q
b
iX
i
pbi q
b
i
⋅100
where q was the quantity in the comparator or base
country (i.e., doses or grams). Finally, Fisher indices (IF)
were calculated as
IF ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
IP⋅IL
p
Sensitivity and subgroup analyses
The results of Laspeyres indices can vary depending on
which country is selected as the base, since this
determines which quantity weights are used. For instance,
atorvastatin, a cholesterol-reducing drug, was only the
40th most prescribed generic drug in Germany, in terms
of number of doses sold, whereas it was one of the ten
most prescribed generic drugs in three of the other coun-
tries. As a sensitivity analysis, we re-calculated all the price
indices with France as the base country.
The results of price indices can also differ depending on
whether exchange rates or purchasing power parities (PPPs)
are used to convert monetary values to a common cur-
rency. Since exchange rates are sensitive to currency fluctu-
ations, we re-calculated all of the indices based on PPP
conversion factors. PPPs, which are measured in national
currency units per US dollar, account for cross-country dif-
ferences in the prices of goods and services. In this way,
they equalize the purchasing power of different currencies.
Finally, we compared the prices of generic drugs in dif-
ferent therapeutic subgroups. To do this, we categorized
the 110 active ingredients by anatomical main groups
using the ATC/DDD system developed by the World
Health Organization Collaborating Centre for Drug Statis-
tics Methodology. Additional file 1: Appendix 1 shows the
breakdown of active ingredients by group. We excluded
ingredients that belonged to more than one group. For ex-
ample, timolol is a beta blocker used to treat both high
blood pressure (ATC group C) and glaucoma (ATC group
S). We then compared the prices of the active ingredients
belonging to the two largest groups in our sample: Cardio-
vascular system drugs (n = 25) and nervous system drugs
(n = 29). The subgroup analysis used exchange-rate con-
versions and Germany as the base country.
The full results of the sensitivity and subgroup ana-
lyses can be found in Additional file 1: Appendices 2–4.
Results
Ex-manufacturer vs. retail prices
Table 1 summarizes the main results with Germany as
the base country. Prices varied markedly across countries.
Denmark and Sweden consistently had the lowest ex-
manufacturer and retail prices among the seven countries,
while France and Italy had the highest in most of the
weighted indices. In the Laspeyres (dose) index, for ex-
ample, the Italian ex-manufacturer prices were, on
average, 1.6 times the German ones and 2.6 times the
Danish ones. Figure 1a shows that while Belgium, France,
and Spain all had higher ex-manufacturer prices than
Germany, the opposite was true about their retail prices,
based on a Laspeyres dose index.
Unit of volume (doses vs. grams of active ingredient)
The results of the unweighted indices fluctuated widely
depending on which unit of volume was used (Table 1).
By contrast, most of the weighted results remained simi-
lar across the two units of volume.5 There were some
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Table 1 Ex-manufacturer and retail prices with Germany as the base country (2013)
Belgium Denmark France Germany Italy Spain Sweden
Ex-manufacturer
Unweighted-D 78.05 48.02 99.31 100.00 109.84 136.86 65.36
Unweighted-G 115.45 55.07 63.62 100.00 50.57 63.09 57.28
Laspeyres-D 136.67 61.11 144.46 100.00 156.66 134.47 85.70
Laspeyres-G 126.90 68.63 164.92 100.00 154.20 124.26 101.59
Paasche-D 108.75 34.38 87.07 100.00 105.59 78.32 56.50
Paasche-G 97.19 39.96 87.55 100.00 63.88 65.26 67.43
Fisher-D 121.92 45.84 112.15 100.00 128.62 102.62 69.58
Fisher-G 111.06 52.37 120.16 100.00 99.24 90.05 82.76
Retail
Unweighted-D 70.97 48.96 98.38 100.00 117.57 129.61 52.91
Unweighted-G 104.09 58.36 57.03 100.00 56.97 62.75 47.49
Laspeyres-D 92.23 48.29 97.06 100.00 114.67 86.01 59.12
Laspeyres-G 87.29 54.93 114.85 100.00 112.28 79.22 69.87
Paasche-D 70.46 32.50 62.17 100.00 76.27 46.43 44.01
Paasche-G 63.99 37.28 62.92 100.00 47.73 40.55 52.69
Fisher-D 80.61 39.61 77.68 100.00 93.52 63.19 51.01
Fisher-G 74.73 45.25 85.01 100.00 73.20 56.68 60.68
D doses, G grams of active ingredient
Source: IMS Health 2013 (Pricing Insights database)
a b
c d
Fig. 1 Results for different price indices in 2013 with Germany as the base country. For ease of interpretation, the unit of volume is
doses in all the price indices. a Comparison of retail and ex-manufacturer prices (n = 110) in a Laspeyres index. b Contrast of ex-manufacturer
prices (n = 110) in a Laspeyres index with German versus French weights. c Ex-manufacturer prices (n = 110) in weighted and unweighted
indices. d Comparison of ex-manufacturer prices of cardiovascular system drugs (n = 25), nervous system drugs (n = 29), and all drugs (n = 110) in a
Laspeyres index. (Source: IMS Health 2013, Pricing Insights database)
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exceptions: In the Laspeyres indices, for example, the
French ex-manufacturer prices were lower than those in
Italy when doses were used, whereas they were higher
when grams of active ingredients were used (Table 1).
Weighting (Laspeyres vs. Paasche vs. Fisher)
The Paasche indices were always lower than the Laspeyres
indices at both the ex-manufacturer and retail levels
(Table 1 and Fig. 1b). The Fisher results — which are the
geometric means of the Laspeyres and Paasche indices —
fell between the latter two.
Base country
Figure 1c shows that the Laspeyres values dropped in all
countries, except Denmark, when the French weights
were used.6 This indicates that those drugs which were
more highly consumed in France than in Germany were
also cheaper in most of the other countries.
Currency conversion (exchange rates vs. purchasing
power parities)
The results were largely unchanged when PPPs — rather
than exchange rates — were used to convert sales in
local currencies to a common unit. This suggests that
variation in drug prices between these seven countries
was, for the most part, not due to differences in the
costs of goods and services.
Subgroup analyses
Figure 1d shows the ex-manufacturer prices of cardio-
vascular system drugs and nervous system drugs. The
amount of price variation differed across therapeutic
groups. In the full sample, there was a 2.5-fold difference
in prices between the countries with the highest and
lowest prices. By comparison, there were 3.1 and 3.5-fold
differences in the prices of nervous system and cardio-
vascular drugs, respectively. Germany had the second
highest prices for nervous system drugs, whereas it had
among the lowest prices for cardiovascular system drugs.
Discussion
In this analysis, we explored differences in the ex-
manufacturer and retail prices of generic drugs across
seven countries in 2013 using various price indices.
The ex-manufacturer and retail prices varied widely
across countries. This is consistent with earlier studies
comparing the prices of patented drugs at both levels
[1, 13, 14]. More research is needed to disentangle the
impact of supply- and demand-side policies, such as
pricing, reimbursement, prescribing, and substitution
rules, on the ex-manufacturer and retail prices of generics
[26]. Prices variation is also likely due, in part, to differ-
ences in the regulation of wholesaler and pharmacy
margins [1].
There are various methods for comparing drug prices
across settings [25, 27], and they often produce remark-
ably different results. For example, the ex-manufacturer
Laspeyres index (dose) in Table 1 suggests that the
sample of generic drugs was about 60% more expensive
in Italy than in Germany. On the other hand, the ex-
manufacturer Paasche index (grams of active ingredient)
indicates that the sample was about 35% cheaper in Italy
than in Germany.
There were even larger differences between some of
the weighted and unweighted indices. It might be espe-
cially important to use weighted indices when compar-
ing generic drug prices, since studies suggest that these
prices are closely linked to volume [28, 29]. Earlier studies
have shown that the results of unweighted and weighted
indices can differ sharply [4, 25], which is consistent
with our findings. Extreme prices can skew the results
of unweighted indices, so these indices are generally
considered less reliable than weighted ones for compar-
ing drug prices [25].
There is no consensus on which weighting method is
most appropriate for comparing drug prices, as each has
advantages and disadvantages [12, 25]. Academic and gov-
ernment studies have variously calculated unweighted
[9, 10], Fisher [11], Paasche [4, 25], and Laspeyres indi-
ces [4, 17, 25, 30], often using different units of volume
and/or base countries. The likely reason why Paasche
results are usually lower than Laspeyres results, a find-
ing which has been reported in previous drug price in-
dices [4, 25], is that patients tend to consume more of
the drugs that are cheaper in their countries. Therefore,
when prices are weighted by local consumption, the in-
dices show lower average prices — relative to the base
country — than when prices are weighted by consump-
tion in the base country.
The choice of unit of volume can influence the results
if there are large, systematic differences between coun-
tries in the average strength per dose [25]. For example,
previous studies have found that price-index results for
Japan vary significantly depending on whether number
of doses or grams of active ingredient serve as the unit
of volume [3, 4, 17, 18, 25]. The authors of those studies
attributed this finding to the tendency of Japanese clini-
cians to prescribe higher quantities of lower-strength
products.
Despite such methodological challenges, it is still pos-
sible to glean useful information from price indices. In
particular, it is important to look for consistency across
indices. As an example, our results indicate that
Denmark and Sweden had the lowest ex-manufacturer
prices in nearly all weighted indices, regardless of
whether Germany or France served as the base country.
This strongly suggests that generic drugs were cheaper
in Denmark and Sweden in 2013 than in the other five
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countries. By contrast, the French and Italian ex-
manufacturer prices were among the highest in all
weighted indices. Ideally, the results of price indices
should be interpreted alongside other quantitative and
qualitative data about the impact of individual policies
on drug prices. On their own, price indices do not pro-
vide causal evidence on the effects of pricing and reim-
bursement rules, generic substitution laws, and other
factors on the prices of generic drugs.
The findings in this study raise questions which merit
further research. Both Sweden and Denmark operate
tender-like systems for generic drugs,7 which may account
for the low prices observed in each country [31, 32]. Ten-
dering refers to the bulk purchase of generic drugs from
the manufacturers that offer the lowest prices [33]. More
work is needed to understand the impact of tendering on
drug prices, and whether any observed price reductions
can be sustained over time. There is concern that relying
exclusively on tendering to procure generic drugs could
create product shortages, drive generic drug firms out of
business, and lead to higher generic drug prices over time
[33]. There is little evidence, however, on the long-term
effects of tendering.
It is also important to examine why there are large dif-
ferences in the prices of drugs in various therapeutic
areas, both within and between countries. Such variation
may, in part, reflect market factors. For example, the
marketing exclusivity for a drug can expire at different
times across high-income countries depending on when
the drug was approved in each jurisdiction. Also, some
studies have observed an inverse relationship between
the number of competitors in the market and generic
drug prices [34, 35]. The speed of generic entry, in turn,
has been found to be correlated with how much brand-
name firms record in revenue in the years leading up to
patent expiry [36, 37]. In other words, generic firms tend
to prioritize more lucrative drug markets.
Limitations
This study has limitations, most of which are inherent to
drug price indices.
First, the data did not account for confidential dis-
counts, which can be as high as 50% for some generic
drugs in certain countries [38]. All list prices may, there-
fore, not have corresponded to the actual prices paid.
However, if profits from discounts accrue to wholesalers
or pharmacists, then list prices are more important to
payers.
Second, Paasche and Laspeyres indices are under-
pinned by assumptions about the relationship between
generic drug prices and usage which may not always
hold. Specifically, the results of Laspeyres indices are
valid if demand for prescription medicines is price
inelastic. While empirical findings contradict this
assumption [39, 40], the Paasche index instead assumes
that the consumption pattern in the base country would
look exactly like that of the comparator country if both
had the same prices. The latter assumption might be less
likely to hold true, since there are differences between
countries in standards of care, disease prevalence rates,
prescription drug coverage, and patient preferences —
all of which can affect demand [25].
Third, by restricting the analysis to a common sample
of drugs, we reduced the sample size. In some previous
price indices for patented drugs, researchers instead
conducted a series of comparisons between the base
country and one other country at a time, looking at the
drugs available in both countries. Such comparisons,
which are called bilateral analyses, maximize the sample
size for each country pair. We chose to instead calculate
what are known as multilateral indices, which compare
the prices of a sample of drugs available in all study
countries. Multilateral indices provide information on
how prices compare across all the countries rather than
just between each pair. While a common sample might
over-represent older, internationally available products
[25], this is less of a concern when comparing generic
drug prices. However, it is important to note that two
countries with identical prices could show up as hav-
ing differing price levels in a Paasche index if con-
sumption patterns differ. Thus, multilateral price
comparisons using Paasche indices should be interpreted
with caution.
Fourth, we used common units of volume to aggregate
data across formulations of active ingredients [25]. In
using prices per dose, however, we assumed that a dose
of a drug provides the same therapeutic benefit to any
patient, regardless of strength-form combination. By
contrast, prices per gram of active ingredient are sensi-
tive to the selection of drugs, given that drug strengths
often vary considerably between drugs [11]. The price
per defined daily dose is an alternative metric. A defined
daily dose is the “assumed average maintenance dose per
day for a drug used for its main indication in adults.”
[41] We could not identify this dose for each drug in
our dataset, as we did not have information about drug
indications. However, defined daily doses are not always
of equal therapeutic value to all patients, and they may
not accurately reflect consumption patterns [25]. For ex-
ample, a defined daily dose is not adjusted for differ-
ences in the duration of treatment. They are, therefore,
not necessarily a better unit of comparison than doses
or grams of active ingredient [25, 41]. Also, because de-
fined daily doses are specified in terms of grams of active
ingredient per day, indices based on defined daily doses
and indices based on grams should generate similar find-
ings if the average number of treatment days are fairly
consistent across countries for most drugs [4].
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Fifth, the drugs were listed by active ingredient, and
no information was available on the indications for
which the drugs were prescribed. However, a prior
study found that the results of price indices were
“virtually unchanged” when products were defined by
active ingredient instead of active ingredient plus
indication [25].
Lastly, we had to exclude 6.7% of drugs (213/3156)
due to missing volume data.
Conclusions
Generic drug policy is an important topic given rising
drug expenditures and concerns about the financial sus-
tainability of many health-care systems. More research is
needed to better understand the causes of variation in
the prices of generic drugs across countries. This will
help to identify which measures are most effective at re-
ducing prices. Our findings suggest that some countries
should focus on containing the distribution costs for
generic drugs.
There are a number of methodological issues that
can arise when trying to compare drug prices inter-
nationally. Drugs often differ across countries in
terms of names, pack sizes, formulations, strengths,
and manufacturers. They can also vary in terms of
whether they are sold over-the-counter or through
prescriptions, and whether they are sold in hospital
or retail pharmacies. There is a trade-off between
matching all of these factors — which produces more
accurate price comparisons of individual products —
and the sample size.
Once a sample of drugs has been chosen, there are
various ways of calculating price indices to aggregate
the data, each with its own advantages and disadvan-
tages, as discussed in this paper. There is no gold
standard for comparing drug prices. Our results
showed that such comparisons are highly sensitive to
the choice of method — for example, Laspeyres ver-
sus Paasche indices — which is consistent with the
findings of earlier studies of patented drugs.
Overall, price indices are a useful statistical approach
for comparing drug prices across countries, but policy-
makers and researchers should interpret price indices
with caution given their limitations.
Endnotes
1The dataset excluded generic drugs sold in hospital
pharmacies, off-patent originator drugs, parallel-traded
products, and off-patent biological drugs.
2IMS Health refers to doses as “standard units.”
3These values were calculated by multiplying the num-
ber of packs sold of each product by the corresponding
prices on a quarterly basis. For these calculations, IMS
Health relied on the latest prices in each quarter from
validated sources, such as government price lists and
wholesaler invoices, excluding value-added taxes.
4If sales of either <1,000 doses or < €1,000 were recorded
in a country for a drug, we decided a priori to exclude the
sales figures for that country, as was done in previous stud-
ies. Those values may reflect data-entry errors or inconsist-
encies in reporting across countries.
5For the common sample of 110 active ingredients, the
average number of grams of active ingredient per dose
ranged from 0.09 grams in Sweden to 0.19 grams in
Spain.
6For ease of comparison to the other results, all prices
are expressed in relation to those in Germany (index
value = 100).
7National government authorities in Denmark and
Sweden operate tender-like systems: the relevant author-
ity in each country asks drug makers to offer their best
prices, and, in most cases, the cheapest products are the
only ones which public payers will reimburse. This
bidding process is repeated every two and four weeks in
Denmark and Sweden, respectively. Payers in Germany
and Spain also tender for generic drugs, but the tender
results were kept confidential in 2013. The data, there-
fore, did not reflect tendering outcomes in either
country.
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Additional file 1: Appendix 1. List of the 200 most-prescribed off-patent
active ingredients in Europe in 2013 (anatomical main group in
parentheses). Appendix 2. Ex-manufacturer and retail prices with
France as the base country (2013). Appendix 3. Ex-manufacturer and
retail prices based on PPP adjustments with Germany as the base country
(2013). Appendix 4. Ex-manufacturer and retail prices of cardiovascular and
nervous system drugs with Germany as the base country (2013). (DOCX 58 kb)
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